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Typhoid fever is a systemic infection caused by
Salmonella enterica serotype typhi (S typhi). A very
similar but often less severe disease is caused by
S paratyphi A, B, and sometimes C. S typhi, a highly
adapted human-specific pathogen that evolved about
50 000 years ago,1 has remarkable mechanisms for
persistence in its host.2
The incidence of typhoid fever has declined greatly
with the provision of clean water and good sewage
systems in Europe and the USA since the early 20th
century,3 but the disease remains a serious public-health
problem in developing countries.4 The advent of
chloramphenicol treatment changed the perception of
typhoid fever from a severe, often fatal, disease to a
common, readily manageable infection.5 Outbreaks of
chloramphenicol-resistant typhoid were reported in
1972.6 At this time, the isolates were still sensitive to co-
trimoxazole and ampicillin or amoxycillin. In the late
1980s and 1990s, outbreaks of typhoid caused by
organisms resistant to chloramphenicol, co-trimoxazole,
ampicillin, and amoxicillin were reported.6 Currently,
fluoroquinolones and third-generation cephalosporins
are the drugs of choice for treatment of typhoid fever,
but decreased susceptibility to these antimicrobials has
been reported.7–10 There is an urgent need to keep the
possible emergence of untreatable strains to a
minimum, by prudent use of existing drugs and by
resisting the temptation to use yet more antimicrobials.
Disease burden
Typhoid is estimated to have caused 21·6 million
illnesses and 216 500 deaths globally in 2000.4 The
incidence of typhoid was high (100 cases per
100 000 population per year) in south-central Asia,
southeast Asia, and possibly southern Africa, medium
(10–100 cases per 100 000) in the rest of Asia, Africa,
Latin America, and Oceania, except for Australia and
New Zealand, and low in the other parts of the world
(10 cases per 100 000). These estimates are based on
blood-culture-positive cases in 22 population-based
studies, many of which11–21 were done after publication of
the previous global estimates (table 1).22 These estimates
have important limitations, however. They are based on
data from only a few countries, with only one study
providing data from Africa. Placebo groups from typhoid
vaccine trials were included, and vaccine trials are
usually done in areas with high disease burden. Some
assumptions used also merit consideration. An
adjustment factor of two was used to account for the low
sensitivity of blood culture. A conservative case-fatality
rate of 1% was chosen on the basis of conservative
estimates of hospital based typhoid fever studies.
Further, there are important consequences of typhoid
fever related to absenteeism from work and need for
admission, which were not considered.
Where typhoid is endemic, most cases in health
facilities are children aged 5–19 years and young adults.
Recent population based studies from India, Indonesia,
and Vietnam suggest that in some settings typhoid fever
is also common in 1–5 year-old children (table 2).15,17,19,20
Data from hospital-based studies in Bangladesh and
Thailand23,24 support these findings. Surveillance data
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Typhoid fever is estimated to have caused 21·6 million illnesses and 216 500 deaths globally in 2000, affecting all
ages. There is also one case of paratyphoid fever for every four of typhoid. The global emergence of multidrug-
resistant strains and of strains with reduced susceptibility to fluoroquinolones is of great concern. We discuss the
occurrence of poor clinical response to fluoroquinolones despite disc sensitivity. Developments are being made in
our understanding of the molecular pathogenesis, and genomic and proteomic studies reveal the possibility of new
targets for diagnosis and treatment. Further, we review guidelines for use of diagnostic tests and for selection of
antimicrobials in varying clinical situations. The importance of safe water, sanitation, and immunisation in the
presence of increasing antibiotic resistance is paramount. Routine immunisation of school-age children with Vi or
Ty21a vaccine is recommended for countries endemic for typhoid. Vi vaccine should be used for 2–5 year-old
children in highly endemic settings.
Search strategy and selection criteria
We searched MEDLINE, PubMed, EMBASE, and the Cochrane
Library from 1995 to 2004 to identify recent studies on the
causative organism, disease burden, transmission, risk
factors, pathogenesis, diagnosis, treatment, and prevention
of typhoid and paratyphoid fevers. The main search terms
were “typhoid fever”, “paratyphoid fever”, “enteric fever”,
and “Salmonella” in combination with “Typhi” or “Paratyphi”.
No language restrictions were applied. We mainly selected
articles in the past 5 years, but did not exclude commonly
referenced and highly regarded older reports. We also
searched the reference lists of articles identified by this search
strategy. Of all articles identified, 1253 were reviewed for
inclusion by two of us (RB and SB). Selection criteria included
a judgment about the novelty and importance of studies and
their relevance for the well-informed general clinician. Several
review articles were included because they provide
comprehensive overviews that are beyond the scope of this
Seminar.
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from the USA indicate that the proportion of cases of
typhoid is constant over the first 25 years of life.4
Typhoid fever is more common in urban than in rural
areas, but studies from two rural settings in Nepal and
Vietnam also found a high disease burden.19–21 Most
cases in developed countries arise in travellers, but
domestically acquired disease is still reported.25,26 A total
of 1393 typhoid cases were reported between 1994 and
1999 in the USA, 74% of which were related to travel and
the rest of which were acquired domestically; 7% of total
cases were part of recognised outbreaks.27
Paratyphoid fever is estimated to have caused an
additional 5·4 million illnesses in 2000.4 This number is
based on an estimated one case of paratyphoid fever for
every four cases of typhoid fever (table 3).11,12,14–16,19,28
Studies from India and Nepal suggest that in some
settings and times, paratyphoid fever caused by
S paratyphi A can contribute up to half of all cases of
typhoid fever.17, 29–31
About 10% of people recovering from untreated
typhoid fever may excrete S typhi in the stools for at least
3 months. Between 1% and 5% of typhoid patients
become chronic carriers (defined as excretion of S typhi
in urine or stools for more than one year), and the rate is
higher for women, those older than 50 years, and patients
with schistosomiasis, cholelithiasis, carcinoma of the gall
bladder, and other gastrointestinal malignancies.32 Most
chronic carriers are asymptomatic and almost a quarter
may have had no history of typhoid fever. 
Transmission and risk factors
People are the only natural host and reservoir for S typhi.
The pathogen can survive for days in groundwater,
pondwater, or seawater, and for months in
contaminated eggs and frozen oysters.33–36 The infectious
dose is between 1000 and 1 million organisms given
orally.37 The infection is transmitted by ingestion of food
or water contaminated with faeces. Established risk
factors are contaminated water supply, eating ice cream,
flavoured iced drinks or food from street vendors, and
raw fruit and vegetables grown in fields fertilised with
sewage.32,38–42 Other reported risk factors include a history
of contact with other patients before illness, not using
soap for washing hands, poor housing, and past
evidence of infection with Helicobacter pylori28,42–44 The
mechanism of increased risk of typhoid in individuals
with chronic H pylori infection is postulated to be
reduced gastric acidity. Factors within the household
(eg, poor personal hygiene and housing) might be more
important risk factors for typhoid, whereas factors
outside the household (eg, food from street vendors,
flooding) are more important for paratyphoid fever.28 A
possible reason proposed for this difference was the
higher infective dose necessary for paratyphoid, which is
more likely to be present in food from street vendors.
Although chronic typhoid carriers are important for
survival of the pathogen, they are less important as a
direct source of infection in endemic areas than
contaminated water or food.32–46 In the USA, up to 30% of
infections are due to exposure from previously or newly
diagnosed chronic carriers.47
Involvement of host genetic factors has also been
implicated in the pathogenesis of typhoid fever. Work on
typhoid fever patients in Vietnam has suggested an
important role of HLA-linked genes in governing
susceptibility or resistance to this infection. HLA-
DRB1*0301/6/8, HLA-DQB1*0201-3, and tumour
necrosis factor a (TNFA*2-308) were associated with
susceptibility to typhoid fever, and HLA-DRQB1*04 and
HLA-DQB1*0401/2 and TNFA*1(-308) were associated
with lower risk.48 HLA-DRB1*12 is associated with
protection against complicated typhoid fever.49 Similar
studies in other ethnic groups might help in defining the
common HLA genes and the locus of susceptibility.
The pathogen
The causative organism of typhoid fever, belongs to the
family Enterobacteriaciae. Most S typhi isolates from
typhoid fever cases have a polysaccharide capsule (Vi),
which is associated with increased infectiousness and
virulence, but Vi-negative strains can also cause the
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Type of surveillance Age (years) n Incidence per 100 000 per year
Urban
Indonesia15 Passive 3–6 1592 1307
7–19 4711 1172
20–44 3965 182
India17 Active 0–4 1027 2730
5–19 2743 1170
20–40 2684 110
Rural
Vietnam19 Passive 2–4 Not reported 358
5–9 531
10–14 429
15–19 153
20–29 149
30–39 51
Vietnam20 Active 2–4 6017 414
Table 2: Age-specific incidence of culture-proven typhoid fever from population-based studies
Type of surveillance Age (years) n Incidence per 100 000 per year
Urban
Chile11 Passive 5–19 21 904 107
Chile12 Passive 5–19 27 305 227
Chile13 Passive 5–19 10 302 91
China14 Passive 5–19 65 984 22
Indonesia15 Passive 3–44 10 268 810
India16 Passive 0–40 Not reported 290
India17 Active 0–40 6454 980
South Africa18 Active 5–16 11 691 850
Rural
Vietnam19 Passive 0–50 28 239 198
Vietnam20 Active 2–4 6017 414
Nepal21 Active 5–44 3450 655
Table 1: Incidence of culture-proven typhoid fever from population-based studies in urban and rural
settings, published after 1986
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disease.50 Molecular typing techniques show that many
different strains are in circulation in endemic areas but
outbreaks are related to a few strains.51–53 Genetic
variation between isolates has been related to clinical
outcome. Multidrug resistant isolates, for instance,
might be more virulent than sensitive strains,54 and
isolates from fatal cases might be different from
background strains.55
The complete DNA sequence of a multidrug resistant
isolate of S typhi isolate, CT18, shows the number of
predicted genes to be 4599.56 The core region conserved
between species (70–80% of the chromosome) could
represent a gene repertoire associated with basic
functions in the Enterobacteriaceae, such as intestinal
colonisation, survival in the environment, and
transmission. Scattered along this conserved core are
single genes or groups of genes that are specific to
S enterica or indeed to serotype typhi. Up to ten
Salmonella pathogenicity islands have been identified. All
types of S enterica have two large clusters of genes known
as Salmonella pathogenicity island 1 (SPI-1) and SPI-2,
that facilitate invasion of and survival inside host cells.
The S typhi genome also contains SPI-7, which has genes
that code for Vi polysaccharide production as well as
many other genes of unknown function. There are more
than 200 pseudogenes that have clearly been inactivated
by simple point mutations or frameshifts, 145 of them
are present as active genes in S typhimurium.
Significantly, S typhimurium causes a different disease in
people, and has a wider host range than S typhi.56,57 Two
plasmids are present—a larger transmissible one called
pHCM1 that encodes several drug-resistance
determinants, and a smaller one, pHCM2, which is
phenotypically cryptic.57,58
Sequence and microarray analysis of the genome of
S paratypi A indicates that it is similar to that of S typhi,
but that it might have a more recent evolutionary origin.
It has accumulated 173 pseudogenes by comparison with
about 210 of the S typhi.59
Pathogenesis
S typhi, unlike S typhimurium, avoids triggering of an
early inflammatory response in the gut of the human
host, using a stealth approach to allow colonisation of
deeper tissues of the body.2,60 The description of typhoid
fever pathogenesis we provide is based largely on the
murine model in which S typhimurium causes a systemic
infection similar to typhoid.
S typhi probably invades the gut mucosa in the
terminal ileum through specialised antigen-sampling
cells, known as M-cells, which overlie gut-associated
tissue,61 through enterocytes, or via a paracelluar route.62
The bacteria adhere to the intestinal mucosa in the
terminal ileum through interaction with an epithelial
receptor, the cystic fibrosis transmembrane conductance
regulator protein.63 A key, early step in the infectious
process is the induction of intestinal epithelial cells to
increase membrane receptor levels, with enhanced
bacterial ingestion and submucosal translocation.64
Studies of non-typhoidal Salmonella spp indicate that
invasion of non-phagocytic epithelial cells occurs
through the activity of bacterial proteins delivered into
host cells by a type III secretion system, encoded on 
SPI-1.65–67 The formation of an intracellular replicative
niche requires further activity of SPI-1,68 which is
downregulated after a few hours of invasion,69 followed
by activity of a second type-III secretion system, encoded
on SPI-2.70,71
The bacterial invasion leads to infiltration of peripheral
blood leucocytes into the lamina propria. This infiltration
is mediated by cytokine secretion from epithelial cells
induced by bacterial lipopolysaccharide, a component of
the cell wall of gram-negative bacteria. Lipopoly-
saccharide activates transcription factors in lymphocytes
by signalling through a mammalian Toll pathway known
as Toll-like receptor 4 complex.72,73 Invading bacteria are
taken up by macrophages, which undergo salmonella-
induced caspase-1 mediated apoptosis.57
The bacteria reach the intestinal lymphoid tissue, and
are drained into mesenteric nodes, the thoracic duct, and
then the general circulation. This primary bacteraemia
results in the organism reaching the liver, spleen, bone
marrow, and other parts of the reticuloendothelial
system within 24 h of their ingestion, where they survive
and replicate in cells of monocytic lineage.74 Bacteria are
shed back into the bloodstream, marking the onset of the
clinical illness (after an incubation period of 8–14 days)
during which a low level of bacteraemia is sustained. 
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Type of surveillance Age (years) n Incidence per 100 000 per year Ratio of typhoid to paratyphoid cases* 
Vietnam19 Active 2–4 6017 22 18·7
China14 Passive 5–19 65 984 5 4·6
Indonesia15 Passive 3–44 10 268 187 4·3
Chile11 Passive 5–19 21 904 26 (paratyphi B) 4·1
Chile12 Passive 5–19 27 305 37 (paratyphi B) 6·2
Indonesia28 Passive 1–80 Not reported Not reported 3·4
India16 Active 0–40 6454 372 2·6
*Ignoring Vietnamese study in 2–4 year-old children,19 population-based studies report 2·6–6·2 (median 4·2) cases of typhoid fever for each case of paratyphoid fever. These data justify
assumption used in global burden estimates4 that incidence of paratyphoid fever is about a quarter of that of typhoid fever.
Table 3: Incidence of culture-proven paratyphoid fever from population-based studies
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A possible underlying molecular mechanism for
persistence of salmonella in the host, as seen in typhoid
carrier state, has been proposed.2 Differences in mouse
susceptibility to S typhimurium have been linked to the
particular allele of the Nramp1 gene expressed on their
macrophages.75 Nramp1 is involved in controlling
exponential growth of salmonella in the
reticuloendothelial system during the early stages of
infection. Mice expressing the wildtype Nramp1 allele
did not die after oral inoculation with S typhimurium, but
became uniformly persistently infected as did chronic
typhoid carriers.76 Salmonella persisted in small
numbers, mainly in the macrophages of mesenteric
lymph nodes or spleen (or both), despite a robust
antibody response. Reactivation of intracellular
salmonella and systemic spread could be accomplished
by administering antibodies to neutralise interferon ,
suggesting that host cytokine interferon  is important
for suppression of salmonella replication and disease.
Antimicrobial resistance
In late 1987, there was an outbreak of typhoid fever in
China caused by strains resistant to all the first line
antimicrobials (ampicillin, co-trimoxazole, and
chloramphenicol).77 During 1989–1990, there were
reports of similar S typhi strains from India, Pakistan,
and the Arabian Gulf.78–80 Such multidrug resistant
typhoid is now reported from many parts of the world
(figure).38,39,53,54,81–94 Multiple antimicrobial resistance is
mediated through pHCM1 plasmid,95,96 which has 99%
sequence identity with plasmid R27,97 an inc H1
plasmid.95 For at least 74% of the isolates in Vietnam,
endemic and epidemic multidrug-resistant typhoid fever
was due to one or two clones of S typhi carrying a single
resistance plasmid.98
A decreasing trend has been reported in the isolation of
multidrug-resistant S typhi strains from southern Asia.
In a retrospective analysis of blood cultures in a diarrhoea
treatment centre in Bangladesh,99 the rate of multidrug-
resistant S typhi was 0·3% of all blood cultures in 1990, a
peak of 3·2% in 1994, and 1·0% in 1996. The isolation
rate of susceptible S typhi remained remarkably
unchanged (3·3%) during the study. More than 90% of
S typhi strains isolated in 1999 from typhoid patients in a
hospital in New Delhi were sensitive to
chloramphenicol.100 In another study from India,101 all
S typhi isolates were resistant to chloramphenicol in
1991, but chloramphenicol resistance fell to less than
20% by 2000.101
After emergence of multidrug resistance, fluoro-
quinolones (eg, ciprofloxacin, ofloxacin) became the
treatment of choice for typhoid fever. Isolates fully
susceptible to ciprofloxacin by disc testing typically have a
ciprofloxacin minimum inhibitory concentration of less
than 0·03 mg/L and are invariably also susceptible to the
first generation quinolone nalidixic acid. A population of
isolates exists with a minimum inhibitory concentration
of 0·125–1·0 mg/L that seems to be susceptible to
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NAR and multidrug-resistant strains 
reported
Multidrug-resistant (but not NAR) 
strains reported
Typhoid endemic areas where 
multidrug-resisant or NAR strains 
not reported
Figure: Global distribution of antimicrobial resistance in S typhi (1990–2004)
Adapted from Parry and colleagues96 and updated on basis of data from past 3 years.
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ciprofloxacin by disc testing but is associated with clinical
failure and is resistant to nalidixic acid (NAR strains);
such isolates have been reported from several countries
(figure).25,83,84,94,102–108 Single point mutations (Ser-83 to Phe,
Asp-87 to Asn, Ser-83 to Tyr and Asp-87 to Gly) in the
gyrA gene of S typhi and S paratyphi cause this reduced
susceptibility to ciprofloxacin.103,107,109,110 Table 4
summarises key features of NAR isolates.107,108,111,112 The
National Committee for Clinical Laboratory Standards
currently recommends testing of extraintestinal
salmonella isolates for nalidixic acid resistance as a
marker for reduced fluoroquinolone susceptibility.113
This testing is, however, not foolproof—in Europe, 11%
of S typhi strains with decreased ciprofloxacin
susceptibility were sensitive to nalidixic acid.114 Multidrug
resistance as well as reduced susceptibility to
ciprofloxacin has also been reported for S paratyphi A.115
Laboratory diagnosis
Confirmation of typhoid or paratyphoid fever requires
isolation of S typhi or S paratyphi, respectively, from
blood, bone marrow, stool, or duodenal fluid. Cultures
from skin above rose spots, buffy coats, and blood clots
treated with streptokinase have been used.116–119 Bone-
marrow aspirate culture is positive in 80–95% of typhoid
patients.116–118,120 Culturing more than 10 mL of blood is
necessary to match the positivity rate with that of 1 mL of
bone marrow. Bone-marrow cultures are useful for
lengthy illness and antibiotic treatment.118,121,122 Blood
culture is the mainstay of diagnosis. Using standard
broth cultures, salmonella is isolated in 30–90% of
patients with clinical typhoid.118,121,122 Sensitivity decreases
with increasing duration of fever.118 The volume of blood
and the ratio of blood to broth determines blood culture
yield: 10–15 mL of blood is necessary to maintain an
optimum ratio of 1 to 12. 2–4 mL of blood is sufficient in
children who have a greater concentration of bacteria in
their blood.122,123 Failure to maintain ambient
temperatures of 15–40ºC during specimen
transportation, inappropriate laboratory methods, and
antimicrobials compromise the yield.
Stool isolation of S typhi alone is insufficient for
diagnosis and only marginally improves diagnosis by
blood culture. However, it is confirmatory for carrier
detection. Serological tests based on agglutination of Vi
antigens have 70–80% sensitivity and up to 95%
specificity in identifying carriers of S typhi .124
The Widal test identifies the agglutinating antibodies
against the O (somatic) and H (flagellar) S typhi
antigens, which appear a week to 10 days after disease
onset. The sensitivity, specificity, and predictive values
reported from different centres vary because of sharing
of O and H antigens and cross-reacting epitopes with
other Enterobacteriaceae.125 The high number of false-
positive and false-negative Widal test results limit its
clinical usefulness. To make a diagnosis, results from a
single acute sample should be interpreted against the
appropriate local cut-off values or there should be a four-
fold rise in the antibody titres between convalescent and
acute sera.126,127
Some simple inexpensive rapid serological diagnostic
tests for typhoid fever are available (table 5).128–133 In an
evaluation of three commercial kits, the sensitivity and
specificity for identifying blood-culture-positive cases of
typhoid fever was 89% and 53% for multi-test dip-sticks
(PANBIO INDX, Baltimore, MD, USA), 79% and 89%
for typhidot (Malaysian Biodiagnostic Research SDN
BHD, Malaysia), 78% and 89% for tubex test (IDL
Bideh, Solletuna, Sweden) as compared with 64% and
76% for Widal.128
The understanding of genome sequence of S typhi
might now result in identification of specific antibodies
to fimbrial and other antigens.57 Urinary Vi antigen
detection by ELISA within the first febrile week shows
promise, but positivity in brucellosis patients is an
obstacle to further development.134 DNA probes and
PCR-based tests to detect flagellar genes135 are not
routinely useful in developing countries, but they are of
value in surveillance and research. 
Clinical features
The clinical presentation of typhoid fever is very variable,
ranging from fever with little other morbidity to marked
toxaemia and associated complications involving many
systems. In endemic regions, diagnosis can be missed
because of non-specific features like diarrhoea and
vomiting, or predominant respiratory symptoms.17,19
Because of this variable profile, the disease has to be
differentiated from tuberculosis, brucellosis, sepsis due
to other bacterial pathogens, infectious mononucleosis,
anicteric hepatitis, and, infrequently, from leukaemia
and lymphoma. In the days when chloramphenicol was
clinically effective, typhoid fever was largely treated on an
outpatient basis, but with the emergence of multidrug-
resistant strains and decreased susceptibility to
fluoroquinolones, it has acquired a profile of severe
infectious disease that often requires inpatient care. In
developing countries, admission has substantial
consequences for poor families.
An average case of acute non-complicated typhoid
fever has an incubation period of 10–14 days and is
usually associated with prolonged low-grade fever, dull
frontal headache, malaise, myalgia, a dry bronchitic
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Proportion of % patients who failed % cases with faecal carriage
NAR strains on fluoroquinolone treatment during early convalescence
UK111 23% (42/179) 24% (10/42) Not reported
Canada112 33% (7/21) 80% (4/5) Not reported
India107 47% (82/174) 27% (22/82) Not reported
Vietnam108 9% (46/504) 24%* (11/46) 21%† (8/39)
*By comparison, 5% (22/458) of nalidixic-acid-sensitive strains had clinical failure on ofloxacin. †By comparison, 2% (7/383) of
nalidixic-acid-sensitive strains had faecal carriage during early convalescence.
Table 4: Key features of nalidixic-acid-resistant (NAR) strains of S typhi
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cough, anorexia, and nausea. The fever might rise
progressively in a stepwise manner to become persistent
and high grade by the second week of illness.46
Continuous high-grade fever can continue for up to
4 weeks if left untreated, followed by a return to normal
temperature. Malaise and lethargy can continue for a
couple of months later.
Although not present consistently, relative bradycardia
at the peak of high fever is an indicator of typhoid fever.
Coated tongue, alteration of bowel habits varying from
constipation in adults to diarrhoea in children, tender
abdomen, hepatomegaly, and splenomegaly are often
present.96,136 Small erythematous maculopapular lesions
(rose spots) are seen on the back, arms, and legs in up to
a quarter of cases late in the first week of fever,
particularly in fair-skinned people. Rhonchi and scattered
crepts might be heard on chest auscultation. Liver
involvement is common with elevated concentrations of
serum bilirubin and alanine transferase; in endemic
areas, typhoid fever should be a differential diagnosis for
a patient with fever and jaundice.137
Neonatal typhoid fever resulting from vertical
transmission during late pregnancy is a rare but often
life-threatening illness. It usually begins during 3 days of
delivery with fever, vomiting, diarrhoea, and abdominal
distension. There might be significant hepatomegaly and
jaundice. Seizures can occur. It could also present as
asymptomatic persistent excretion. In children younger
than 5 years, typhoid fever can be milder and can mimic
a viral syndrome. The rate of severe complications is
lower than at later ages.17,138
Overall, about 10–15% of patients develop severe
disease. Factors affecting severity include duration of
illness before therapy, choice of antimicrobial therapy,
strain virulence, inoculum size, previous exposure or
vaccination, and other host factors such as HLA type,
AIDS or other immune suppression, or antacid
consumption. The commonest complications are
gastrointestinal bleeding, intestinal perforation and
typhoid encephalopathy.46,96 A rapid drop in temperature
during the later period of the illness suggests intestinal
bleeding or perforation. This drop is usually followed by
a rise in temperature after a few hours as peritonitis
develops. Gastrointestinal bleeding occurs in 10–20% of
cases due to erosion of the Peyer’s patch into an
intestinal vessel and is usually restricted to either occult
blood in stool or malaena. On colonoscopy, terminal
ileum is the commonest site involved followed by the
ileocaecal valve, the ascending then the transverse
colon.139 Multiple punched out ulcers with slightly
elevated margins are evident. 
Intestinal perforation occurs in 1–3% of cases in
hospital; the commonest site is the ileum.140 Being male,
leucopenia, inadequate treatment before admission, and
short duration of symptoms are significant predictors of
perforation.141 Intermittent confusion, insomnia, and
dizziness are reported in 3–10% of cases and these
symptoms are associated with high case fatality. Some
patients manifest neuropsychiatric symptoms such as
picking at bedclothes or imaginary objects, which are
described as muttering delirium or coma vigil. Deep
coma is rare. Typhoid meningitis, encephalomyelitis,
Guillain-Barré syndrome, and cranial or peripheral
neuritis have been reported from different regions with
incidence of 2–40%. Convulsions occasionally arise in
young children.142 Examination of the cerebrospinal fluid
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Antibodies Country Sensitivity Specificity Positive predictive value Negative predictive value
Tubex Immunoglobulin Vietnam129* 87% 76% 77% 84%
S typhi 09 antigen M
Dipstick Immunoglobulin Vietnam129* 48% 98% 99% 65%
S typhi M
Lipopolysacchride antigen
Immunoglobulin Vietnam128† 89% 50% 83% 60%
G
Immunoglobulin Indonesia130† 65·3% 100% 100% 61%
M
Immunoglobulin Indonesia131† 86·5% 88·9% 90·4% 66·6%
M
Typhidot Immunoglobulins Vietnam128† 79% 89% 96% 59%
Dot-ELISA G or M
S typhi 50 RD OMP 
Immunoglobulins  Pakistan132* 94% 77% 88% 87%
G or M, alone or in
combination
Immunoglobulins India133† 100% 80% 83.3% 100%
G + M
Typhidot M Immunoglobulin  Pakistan132* 73% 89% 95% 55%
Dot-ELISA M
S typhi 50 RD OMP 
Studies only included where the gold standards were positive blood or bone-marrow culture (*) or positive blood culture (†). OMP=outer membrane protein.
Table 5: Performance of new diagnostic tests for typhoid fever
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is recommended in patients with behavioural or
neurological manifestations and negative blood cultures
to rule out tubercular meningitis.
Severe complications such as disseminated
intravascular coagulation or haemorrhages can lead
rapidly to death. Severe pneumonia is more frequent in
children than adults. The other rare complications
reported include hepatic, splenic, and bone-marrow
granulomas, splenic and liver abscesses, pleural effusion,
multiple organ dysfunction syndrome, haemato-
phagocytic syndrome, pseudotumour cerebri, haemolytic
uraemic syndrome, glomerulonephritis or pylonephritis,
endocarditis, and pericarditis.143–147 Arrhythmia or
cardiogenic shock can be a manifestation of toxic
myocarditis with fatty infiltration of the heart. 
With the introduction of early and appropriate antibiotic
therapy, the average case fatality rates for typhoid are less
than 1%; however, mortality as high as 30–50% has been
reported from Papua New Guinea and Indonesia for
severe typhoid fever.148,149 In 552 culture-positive patients
with typhoid fever in hospital in Bangladesh, the overall
case-fatality rate was 4·3%, with the highest rates for
those younger than 1 year (11%) and for adults 31 years or
older (10%).142 Further, 5–10% of cases can relapse after
2–3 weeks of resolution of the initial fever, but the clinical
severity of this episode is much lower. Relapse can
happen without a history of therapeutic intervention but
more often it follows antibiotic treatment.150–152 The
incidence ofrelapse after treatment with fluoroquinolones
(1·5%) or broad-spectrum cephalosporins (5%) is lower
than that after treatment with chloramphenicol,
trimethoprim-sulfamethoxazole, and ampicillin.153 Most
relapses are caused by the same S typhi strain with the
same antibiotic susceptibility patterns as the initial
episode. However, some individuals become reinfected
with distinct and possibly newlyacquired isolates.153
Clinical features of paratyphoid fever are similar to
those of typhoid fever but are usually milder with a
shorter incubation period. S paratyphi A or paratyphi B
can manifest with jaundice, thrombosis,154,155 and
systemic infections.156 S paratyphi B might occasionally
have an onset similar to non-specific salmonella
gastroenteritis. Gastrointestinal symptoms are usually
not present with S paratyphi C but there have been cases
with systemic complications such as septicaemia and
arthritis.157 A relapse rate of 8% has been reported with
S paratyphi A.158
Treatment
Important considerations for treatment are the
prevention of severe complications and death, and
prompt resolution of clinical disease. It is also important
to eradicate the organism promptly to prevent relapses
and faecal carriage. More than 90% of patients are
managed at home with oral antimicrobials, bedrest, and
close medical follow up. Patients with persistent
vomiting, severe diarrhoea, or abdominal distension
need admission to hospital and parenteral antibiotic
therapy.46
Typhoid fever should be a serious consideration in an
endemic area when a fever lasts longer than a week, even
by the fifth day if there is severe toxaemia. The decision
to send laboratory investigations and initiate empirical
antimicrobial therapy depends largely on clinical
judgment. Initial choice of antibiotic depends on the
sensitivity patterns of S typhiand paratyphi isolates in the
area. The isolates can be broadly classified as sensitive to
first-line antimicrobials, multidrug resistant but
nalidixic-acid sensitive, and nalidixic-acid resistant
(often also multidrug resistant).
Fluoroquinolones (ciprofloxacin, ofloxacin, and
pefloxacin) are the most effective drugs for treatment of
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First-line oral drug Second-line oral drug
Antibiotic Daily dose (mg/kg) Days Antibiotic Daily dose (mg/kg) Days
Uncomplicated typhoid at home
Fully susceptible Fluoroquinolone 15 5–7 Chloramphenicol 50–75 14–21
Amoxycillin 75–100 14
Trimethoprim 8 (trimethoprim) 14
-sulpfamethoxzole 40 (sulfamethoxazole)
Multidrug-resistant Fluoroquinolone 15 5–7 Azithromycin 8–10
or cefixime 20 7
7–14
Nalidixic-acid resistant Azithromycin 8–10 7 Fluoroquinolone 20 10–14
or cefixime 20 7–14
Severe typhoid in hospital
Fully susceptible Fluoroquinolone 15 10–14 Chloramphenicol 100 14–21
Ampicillin 100 10–14
Multidrug-resistant Fluoroquinolone 15 10–14 Ceftriaxone or 60 10–14
cefotaxime 80
Nalidixic acid resistant Ceftriaxone or 60 10–14 Fluoroquinolone 20 10–14
cefotaxime 80
Adapted from Parry and colleagues.96
Table 6: Antibiotic treatment for typhoid
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typhoid fever caused by isolates that are not quinolone
resistant,159–163 with a clinical cure rate of about 98%, fever
clearance time of about 4 days, and relapse and faecal
carriage rates of less than 2%.96 Chloramphenicol, the
traditional first-line drug of choice, is less effective than
fluoroquinolones in all these respects and in terms of
persistence of the organism in bone marrow, even for
treatment of patients with fully sensitive isolates.96,164
Fluoroquinolones are equally effective for treatment of
typhoid fever in children and adults.165 However, these
drugs are not registered for routine use in children
because of evidence of articular damage in growing,
weight-bearing joints in young beagles.166,167 Extensive
experience of these drugs in children with typhoid, cystic
fibrosis, and dysentery has shown no evidence of bone or
joint toxicity, and impairment of linear growth.168–172
Where multidrug resistant strains are common and
third-generation cephalosporins unavailable, fluoro-
quinolones can be used for treatment of typhoid fever in
children.
Short courses of ofloxacin given for 2, 3, or 5 days
treated more than 90% of patients infected with
multidrug resistant but nalidixic-acid susceptible
isolates of S typhi, with an average fever clearance
time of 4 days. Less than 3% of patients relapsed or
had a positive posttreatment stool culture. Such short-
term regimens are especially useful in control of
epidemics. By contrast, the response of NAR isolates to
such regimens is poor. Ofloxacin given for 7 days
cured only 75% of patients infected with NAR isolates
with a fever clearance time of 7 days, and 19% patients
had a positive posttreatment stool culture.103,108
Azithromycin, and cefixime, an oral third-generation
cepahalosporin, have a clinical cure rate of over 90%
with a fever clearance time of 5–7 days and relapse and
faecal carriage rates of less than 4% in typhoid
fever.108,161–163,173–176 These antimicrobials are therefore
regarded as acceptable therapy for quinolone-resistant
typhoid and paratyphoid fever. Their major limitations
are high cost and low availability (table 6). 
Combinations of antimicrobials are being assessed to
provide more affordable options for treatment of
quinolone-resistant typhoid fever. Ciprofloxacin proved
to be more effective in combination with amoxycillin
than ciprofloxacin alone against S typhi strains in vitro
with a ciprofloxacin minimum inhibitory concentration
of 1 mg/L or more.177 The fractional inhibitory
concentration for ciprofloxacin against these isolates was
0·004–0·256 mg/L when the antibiotic combination was
used.177 Similar findings have been reported for a
combination of ciprofloxacin and gentamicin.178
Supportive treatment includes maintenance of
hydration, appropriate nutrition, and antipyretics. In a
recent study, children with uncomplicated typhoid fever
were randomly assigned to receive either ibuprofen or
paracetamol every 6 h until 36 h after defervescence.179
Median fever clearance time was shorter with ibuprofen
as was the area under the temperature–time curve
above 37ºC. The differences were mainly in children
infected with NAR S typhi who responded slowly to
antibiotic treatment.
Severe typhoid and paratyphoid
Patients with persistent vomiting, severe diarrhoea
or abdominal distension requiring admission, and
those with complications should be treated for severe
typhoid fever. Fluoroquinolones remain the antibiotic of
choice in areas where prevalence of quinolone-resistant
isolates is low even though there have been no
randomised antibiotic trials in patients with
severe typhoid.165 Third-generation cephalosporins
(ceftriaxone or cefotaxime) are recommended where
quinolone resistant isolates are prevalent (table 6).
Antimicrobials should be given parenterally for at least
10 days, or for at least for 5 days after defervescence.180,181
In Pakistan, clinical and bacteriological cure rates were
similar with 7-day or 14-day treatment with intravenous
ceftriaxone, but the confirmed bacteriological relapse
rates were 14% with the 7-day regimen whereas none in
the 14-day treatment group relapsed.187
In Indonesian adults and children with delirium,
obtundation, stupor, coma, or shock, mortality was
reduced from 50% to 10% for those given
dexamethasone as an initial dose of 3 mg/kg by
slow intravenous infusion over 30 min followed by
1 mg/kg at the same rate every 6 h for eight additional
doses.148,183
Patients with intestinal haemorrhage need intensive
care, monitoring, and blood transfusion when blood loss
is substantial. Patients with intestinal perforation should
be resuscitated with fluids or blood and undergo early
surgical intervention within 6 h to prevent death.46
Relapses should be treated in the same way as initial
infections.
Treatment of chronic carriers
Most carriers (defined as individuals who excrete S typhi
in their stools or urine for more than a year) without
gallstones can be cured by a long course of
antimicrobials. Almost 80% of carriers were cured by
750 mg of ciprofloxacin twice daily for 28 days, and 11
out of 12 carriers treated with 400 mg norfloxacin twice
daily had negative stool and bile cultures for S typhi after
28 days of treatment.184,185 In patients with gallstones,
cholecystectomy along with antibiotic therapy might be
required. Carriers should be excluded from any activities
involving food preparation and serving, as should be
people recovering from typhoid fever. 
Prevention
The key preventive strategies are safe water, safe food,
personal hygiene, and appropriate sanitation.46 The
importance of prevention has greatly increased with
the emergence of antibiotic resistance. However,
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provision of safe water and appropriate sanitation are
expensive and are usually linked with economic
development. Vaccination is an additional effective tool
for prevention of typhoid fever. Vaccination is useful
for prevention of typhoid in travellers from developed
countries to typhoid endemic countries, in preventing
and controlling epidemics, as well for children in
endemic settings aged 2–19 years.46
Most cases of typhoid fever in developed countries
are a result of travel to endemic disease areas. Six
countries—India, Pakistan, Mexico, Bangladesh, the
Philippines, and Haiti—accounted for 76% of travel
associated cases.186 37% of these cases were in people
who stayed at their travel destination for 4 weeks or less
and 16% were in people who stayed for 2 weeks or less.
80% cases were in people visiting relatives and friends.
Travellers to these countries, especially those visiting
for 2 weeks or more and those visiting friends and
relatives, should be targeted for vaccination.
The old parenteral whole-cell typhoid-paratyphoid A
and B vaccine was effective against both typhoid and
paratyphoid fevers but has been largely discontinued
because of strong side-effects.187 Two vaccines for
typhoid fever, one based on Vi polysaccharide and the
other on whole-cell live attenuated bacteria, are
currently licensed. A new Vi-conjugate vaccine is
highly effective in children younger than 5 years but it
has not been tested in infants. Currently, there is no
licensed vaccine for paratyphoid fever.
Vi polysaccharide vaccine
This vaccine is licensed for use in individuals older
than 2 years and is given in a single subcutaneous
or intramuscular dose. The vaccine is moderately
effective for about 3 years after vaccination
(table 7).14,21,188,189 Revaccination is recommended every 3
years. However, 58% of participants in a field trial in
South Africa still had protective levels of antibodies 10
years after vaccination.192 This vaccine has shown about
70% protective efficacy in a population vaccinated
before or during an outbreak in China.189 The Vi vaccine
can be given simultaneously with other vaccines
relevant for international travellers such as yellow fever
and hepatitis A.190,191,193
Ty21a vaccine
This live oral vaccine available in enteric-coated or
liquid formulation is approved for use in people 6 years
of age and older. The liquid formulation for younger
children is currently marketed in only a few countries.
Three doses are recommended each given 2 days apart.
Antimicrobials should be avoided for 7 days before or
after vaccination. The vaccine is moderately effective for
up to about 3 years after vaccination (table 7).11–13,15,194,195 A
booster dose is recommended every 3 years in endemic
areas and travellers should be revaccinated annually.
Herd immunity was shown during field trials in
Chile.11,13 The vaccine can be given simultaneously with
other vaccines and with antimalarial prophylaxis.196
The effectiveness of both these licensed vaccines in
developing countries is similar. Ty21a has the
advantage that it is given orally and therefore might be
easier for immunising groups of children, as in
schools. The Ty21a vaccine, especially the enteric-
coated capsule formulation, is not licensed for use in
2–5 year-old children. Vi vaccine has a relative
advantage that it can be used for these preschool
children, in settings where typhoid fever is common in
this age-group. The vaccine however, is not licensed for
use in children younger than 2 years. 
Post-marketing surveillance for typhoid fever
vaccines from the Vaccine Adverse Effects Reporting
System from 1990 to 2002 has shown rare reports of
death, admission, permanent disability, or life-
threatening illness.197 Unexpected frequently reported
symptoms included dizziness and pruritis for Vi
vaccine and fatigue and myalgia for Ty21a.
Gastroenteritis for Ty21a and abdominal pain after Vi
vaccine are previously recognised events.
Vi-conjugate vaccine
Vi-conjugate vaccine given to 2–5 year-old Vietnamese
children had 91·1% protection against typhoid
27 months after vaccination, with geometric mean
titres of 7·61 ELISA units for those vaccinated at age
2–3 years.20 The efficacy of this conjugate persisted after
46 months of vaccination: over the entire period the
protection was 89% (95% CI 76%–97%).198 Based on the
antibody titres after 46 months of vaccination, the
researchers suggest a protective level of antibody to
immunoglobulin G to be reduced from 7 to 3·52
ELISA units. This vaccine could be used for children
younger than 2 years and be incorporated into the
Expanded Programme on Immunization immuni-
sation schedules.
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Age range Follow up Dose Protective efficacy
(years) (years) (95% CI)
Vi vaccine
Nepal21 5–44 1·5 Single dose 72% (41–87)
South Africa186 5–16 3 Single dose 55% (30–71)
China14 3–19 1·5 Single dose 69% (28–87)
China187 12–21 Immunised during Single dose 71% (34–87) 
epidemic or up to  
1 year earlier
Ty21a vaccine
Egypt194 6–7 3 3 doses (enteric coated capsules) 96% (67–99)
Chile11 6–21 3 3 doses  (enteric coated capsules) 67% (47–79)
Chile13 5–19  3 3 doses (enteric coated capsules) 33% (0–57)
3 doses/liquid 77% (60–87)
Chile12 5–22 2 2 doses  (enteric coated capsules) 59% (41–71)
Chile195 6–19 5 3 doses (liquid) 78% (65–87)
Chile195 6–19 7 3 doses (enteric coated capsules) 62% (48–73)
Indonesia15 3–44 2·5 3 doses  (enteric coated capsules)  42% (23–57)
3 doses (liquid) 53% (33–66)
Table 7: Effectiveness of two typhoid vaccines
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Vaccines under development
Vaccines are under development based on outer
membrane proteins known as porins and new live oral
vaccines (eg CVD 908-htrA and Ty2 candidate
vaccines).199–201 A new vaccine against S paratyphi A
composed of surface-O-specific polysaccharide conju-
gated with tetanus toxoid has proved safe and
immunogenic.202 Live typhoid vaccines are being devel-
oped as a vector for immunisation against H pylori.203
Conclusion
Typhoid fever is an important public-health problem in
south-central and southeast Asia, the middle east, Africa,
and South America, mainly affecting children and young
adults. Treatment of typhoid fever is becoming more
difficult with multidrug resistant organisms also
acquiring some resistance to fluoroquinolones. Fully
ciprofloxacin-resistant S typhi has not been reported,
although full resistance in non-typhoid salmonella has
emerged.204,205 Effective immunisation and non-vaccine
based prevention strategies are available and are
becoming more important in the face of increasing
antibiotic resistance.
S typhi is restricted to human beings. The organism
does not persist long in any environmental reservoir after
its elimination from local regions. The analysis of
individual pseudogene mutations from S typhi isolates
shows that different isolates harbour the same mutations.
This strongly suggests that the organism has emerged
only once and cannot readily evolve from other S typhi
serotypes.53 Improved sanitation, better diagnostics for
early detection and treatment of patients and carriers, and
mass vaccination are effective interventions in combating
typhoid fever. All these factors indicate that global
eradication of typhoid is theoretically possible and merits
consideration as a global health issue.
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